title: Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
abstract: To confirm the clinical utility of selegiline (L-deprenyl), a selective inhibitor of monoamine oxidase B, as an anti-Parkinson's disease (PD) agent, the first Japanese multi-center, double-blind comparative study of this drug was conducted. The subjects were patients who had responded poorly or suffered with other problems related to L-dopa treatment. A total of 112 patients in two groups, one given selegiline at a dose of 7.5 mg/day (Group D, n = 60) and another given a placebo (Group P, n = 52), were compared over an 8-week treatment period. The percentage patients showing "moderate improvement" or better was 34.5% in Group D, while that in Group P was 11.5% (P < 0.01). In the assessment of overall safety, 66.7% in Group D showed no adverse reactions, which was not significantly different from the result of 78.9% for Group P.
authors.affiliation: Department of Neurology, Kinki University School of Medicine, Osaka-sayama.
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: R
authors.initials: R
authors.lastname: Yuasa
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: H
authors.initials: H
authors.lastname: Tachibana
authors.forename: S
authors.initials: S
authors.lastname: Yorifuji
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D012642:Selegiline; D007980:Levodopa